In this thesis interactions in complex fluids, such as serum and meat juice, were analysed with optical biosensor techniques. Panels of lectins immobilised on gold surfaces were used for investigation of differences in protein glycosylation pattern in sera and meat juices between various species. The present panel was also used for investigation of global glycosylation changes of serum proteins in type 1 diabetes patients. Biorecognition was evaluated with null ellipsometry and scanning ellipsometry combined with multivariate data analysis techniques (MVDA). Principal component analysis (PCA) showed that the lectin panel enabled discrimination between sera from the different species as well as for the different meat juices. The results also indicate that there is a measurable global alteration in glycosylation pattern of serum proteins in type 1 diabetic patients compared to healthy subjects. Using an artificial neuronal net (ANN), it was also possible to correctly categorise unknown serum samples into their respective class or group. The analytical potential of combining information from lectin panels with multivariate data analysis was thereby demonstrated. Also, a sensitive and specific method based on surface plasmon resonance (SPR) for detection of insulin autoantibodies (IAA) in serum samples from individuals at high risk of developing type 1 diabetes (T1D) has been developed. When measuring trace molecules, such as autoantibodies, in undiluted sera with label-free techniques like SPR, non-specific adsorption of matrix proteins to the sensor surface is often a problem, since it causes a signal that masks the analyte response. The developed method is an indirect competitive immunoassay designed to overcome these problems. Today, IAA is mainly measured in radio immunoassays (RIAs), which are time consuming and require radioactively labelled antigen. With our SPR-based immunoassay the overall assay time is reduced by a factor of >100 (from 4 days to 50 min), while sensitivity is maintained at a level comparable to that offered by RIA. Finally, the assay was used in a screening study of newly diagnosed type 1 diabetes patients and non-diabetic subjects.

Vibrio cholerae, the causal agent of cholera typically encodes two critical virulence factors: cholera toxin (CT), which is primarily responsible for the diarrhoeal purge, and toxin-co-regulated pilus (TCP), an essential colonisation factor. Nontoxigenic strains expressing TCP can efficiently acquire the CT gene through lysogenic conversion with CTXΦ, a filamentous phage that encodes CT and uses TCP as a receptor.  V. cholerae is a Gram-negative bacterium and a natural inhabitant of estuarine and coastal waters throughout both temperate and tropical regions of the world. In the aquatic environment, V. cholerae encounters several environmental stresses, such as change in salinity, UV stress, nutrient limitation, temperature fluctuations, viral infections and protozoan predation. To fully understand the pathogenic and virulence potential of V. cholerae, knowledge is required of its interactions with, not only human, but also environmental factors. By using the nematode Caenorhabditis elegans as host model, we were able to identify a previously uncharacterised protein, the extracellular protease PrtV. PrtV was shown to be required for the killing of. elegans and also necessary for survival from grazing by the ciliate Tetrahymena pyriformis and the flagellate Cafeteria roenbergensis. The PrtV protein, which belongs to a M6 family of metallopeptidases was cloned and purified for further characterisations. The purified PrtV was cytotoxic against the human intestinal cell line HCT8. By using human blood plasma, fibrinogen, fibronectin and plasminogen were identified as candidate substrates for the PrtV protease. Outer membrane vesicles (OMVs) are released to the surroundings by most Gram-negative bacteria through “bulging and pinching” of the outer membrane.  OMVs have been shown to contain many virulence factors important in pathogenesis. Therefore, we investigated the association of PrtV with OMVs. PrtV was not associated with OMVs from the wild type O1 strain. In contrast, in an LPS mutant lacking two sugar chains in the core oligosaccharide PrtV was found to be associated with the OMVs. The OMV-associated PrtV was shown to be proteolytically and cytotoxically active. V. cholerae strains are grouped into >200 serogroups. Only the O1 and O139 serogroups have been associated with pandemic cholera, a severe diarrhoeal disease.  All other serogroups are collectively referred to as non-O1 non-O139 V. cholerae. Non-O1 non-O139 V. cholerae can cause gastroenteritis and extraintestinal infections, but unlike O1 and O139 strains of V. cholerae, little is known about the virulence gene content and their potential to become human pathogens. We analysed clinical and environmental non-O1 non-O139 isolates for their putative virulence traits. None of them carry the genes encoding CT or the TCP, but other putative virulence factors were present in these isolates. The incidence of serum resistance was found to vary considerably and was independent of encapsulation. Three strains were strongly serum-resistant, and these same strains could also kill C. elegans.

BACKGROUND: Serum amyloid P component (SAP) is a glycoprotein that is universally found associated with different types of amyloid deposits. It has been suggested that it stabilizes amyloid fibrils and therefore protects them from proteolytic degradation. METHODOLOGY/PRINCIPAL FINDINGS: In this paper, we show that SAP binds not only to mature amyloid fibrils but also to early aggregates of amyloidogenic mutants of the plasma protein transthyretin (TTR). It does not inhibit fibril formation of TTR mutants, which spontaneously form amyloid in vitro at physiological pH. We found that SAP prevents cell death induced by mutant TTR, while several other molecules that are also known to decorate amyloid fibrils do not have such effect. Using a Drosophila model for TTR-associated amyloidosis, we found a new role for SAP as a protective factor in inhibition of TTR-induced toxicity. Overexpression of mutated TTR leads to a neurological phenotype with changes in wing posture. SAP-transgenic flies were crossed with mutated TTR-expressing flies and the results clearly confirmed a protective effect of SAP on TTR-induced phenotype, with an almost complete reduction in abnormal wing posture. Furthermore, we found in vivo that binding of SAP to mutated TTR counteracts the otherwise detrimental effects of aggregation of amyloidogenic TTR on retinal structure. CONCLUSIONS/SIGNIFICANCE: Together, these two approaches firmly establish the protective effect of SAP on TTR-induced cell death and degenerative phenotypes, and suggest a novel role for SAP through which the toxicity of early amyloidogenic aggregates is attenuated. / <p>Epub 2013 Feb 4.</p>

This thesis is about protein profiling in blood-derived samples using suspension bead ar- rays built with protein affinity reagents, and the evaluation of binding characteristics and potential disease relation of such profiles. A central aim of the presented work was to discover and verify disease associated protein profiles in blood-derived samples such as serum or plasma. This was based on immobiliz- ing antigens or antibodies on color-coded beads for a multiplexed analysis. This concept generally allow for a dual multiplexing because hundreds of samples can be screened for hundreds of proteins in a miniaturized and parallelized fashion. At first, protein antigens were used to study humoral immune responses in cattle suffering from a mycoplasma infec- tion (Paper I). Here, the most immunogenic of the applied antigens were identified based on reactivity profiles from the infected cattle, and were combined into an antigen cocktail to serve as a diagnostic assay in a standard ELISA set-up. Next, antibodies and their em- ployment in assays with directly labeled human samples was initiated. This procedure was applied in a study of kidney disorders where screening of plasma resulted in the discovery of a biomarker candidate, fibulin-1 (Paper II). In parallel to the disease related applica- tions, systematic evaluations of the protein profiles were conducted. Protein profiles from 2,300 antibodies were classified on the bases of binding properties in relation to sample heating and stringent washing (Paper III). With a particular focus on heat dependent de- tectability, a method was developed to visualize those proteins that were captured to the beads in an immunoassay by using Western blotting (Paper IV). In conclusion, this thesis presents examples of the possibilities of comparative plasma profiling enabled by protein bead arrays. / <p>QC 20130208</p>

Male rat mating is a suite of individual behaviors mediated by the actions of two metabolites of testosterone (T), dihydrotestosterone (DHT) and estradiol (E2), on the brain. Individually, neither metabolite fully maintains or restores mating in castrated males, but both combined are as effective as T. Two hormone-responsive areas of the brain, the medial preoptic area (MPO) and the medial amygdala (MEA), are crucial for mating. These studies ask: by what mechanism(s) does E2 act in the MPO and MEA? We blocked the conversion of T to E2 in the MEA of intact male rats and sexual behavior was not maintained. We then infused antisense oligodeoxynucleotides (ODNs) to estrogen receptor-alpha (ER-á) mRNA bilaterally to the MPO or the MEA of intact male rats to block ER-á expression. ODN infusion of the MPO attenuated mating but infusion of the MEA had no effect. These results suggest that ER-á is the behaviorally relevant estrogen receptor (ER) in the MPO but not in the MEA. ER was originally described in the cytoplasm and nucleus of cells. Recently plasma membrane associated ERs (mER) have been reported. We conjugated E2 to Bovine Serum Albumin (BSA-E2), a large protein that will not penetrate the plasma membrane, thus restricting the action of E2 to mER, and chronically delivered it to the MPO and MEA. BSA-E2 maintained mating if put in the MPO, but not in the MEA, suggesting a surface action of E2 is sufficient in the MPO. The MPO and MEA are reciprocally connected and probably constitute elements of a larger, steroid-responsive neural network that mediates male mating behavior. To begin to describe this purported circuit, we injected Pseudorabies virus (PRV) into the prostate gland and dually labeled PRV-immunoreactive cells for ER or androgen receptors. We found dual labeling in a forebrain diencephalic circuit that includes the MPO, the medial preoptic nucleus, bed nucleus of stria terminalis, the zona incerta, the periaqueductal gray and other areas that presumably mediate both autonomic and motor aspects of male mating. Together, the results of these studies begin to elucidate locations and mechanisms of E2 mediation of male sexual behavior.

Measuring HPV exposure relies on detection of HPV type-specific antibodies, but methods are not standardized. Additionally, there is little information on the best sample type for HPV antibody detection. This study validated pseudovirion neutralization (PVN) assay for HPV antibody detection and compared it to IgG ELISA. Both assays were applied to paired serum and cervical mucus samples. Additionally, PVN assay was utilized to evaluate the feasibility of oral mucosal transudate (OMT) samples to monitor the HPV immune response. Serum was more likely to be positive on PVN assay than on IgG ELISA (p= 0.025). Both assays correlated with HPV-16 DNA status. HPV-18 PVN assay results correlated with HPV-18 DNA status. Few cervical mucus samples had detectable antibodies; no correlation with HPV DNA status was seen. OMT results were unsatisfactory. PVN assay was more sensitive than IgG ELISA; serum was a more reliable indicator of HPV-16/18 antibody status than cervical mucus.

Embryogenesis occurs within a complex and dynamic cellular environment that influences cell fate decisions. Pluripotent stem cells (PSCs) are a valuable tool for research into disease models as well as a resource for cell therapy due to their capacity to self-renew and differentiate into all cell types. Mimicking aspects of the embryonic microenvironment in vitro impacts the resultant functional cells. The aim of this work was to develop a controlled and scaleable process for the generation of hematopoietic progenitor cells (HPCs) from embryonic stem cells (ESCs). We demonstrated with bioreactor-grown embryoid bodies (EBs) that increased HPC generation can be elicited by decreasing the oxygen tension by a mechanism where vascular endothelial growth factor receptor 2 (VEGFR2) activation is controlled through competition with the ligand decoy VEGFR1. This is important as it demonstrates the inherent responsiveness of the developing hematopoietic system to external forces and influences. We also established a serum-free system that facilitates directed differentiation, determining 5 ng/ml bone morphogenetic protein-4 (BMP4) with 50 ng/ml thrombopoietin (TPO) could generate 292 ± 42 colony forming cells (CFC)/5 x 10^4 cells with early VEGF treatment (25 ng/ml, day 0-5). We also controlled aggregate size influencing relative endogenous and exogenous growth factor signaling and modulating mesodermal differentiation; CFC output was optimal when initialized with 100 cell aggregates. For the first time, we demonstrated efficacy of local growth factor delivery by producing HPCs with gelatin microparticles (MP). Overall, these design components generate HPCs in a controlled and reproducible manner using a serum-free bioprocess that couples size controlled aggregates containing gelatin MPs for localized growth factor release of BMP4 and TPO with hypoxia to induce endogenous VEGF production. These strategies provide a tunable platform for developing cell therapies and high density growth, within a bioreactor system, can be facilitated by hydrogel encapsulation of the aggregates.

Embryogenesis occurs within a complex and dynamic cellular environment that influences cell fate decisions. Pluripotent stem cells (PSCs) are a valuable tool for research into disease models as well as a resource for cell therapy due to their capacity to self-renew and differentiate into all cell types. Mimicking aspects of the embryonic microenvironment in vitro impacts the resultant functional cells. The aim of this work was to develop a controlled and scaleable process for the generation of hematopoietic progenitor cells (HPCs) from embryonic stem cells (ESCs). We demonstrated with bioreactor-grown embryoid bodies (EBs) that increased HPC generation can be elicited by decreasing the oxygen tension by a mechanism where vascular endothelial growth factor receptor 2 (VEGFR2) activation is controlled through competition with the ligand decoy VEGFR1. This is important as it demonstrates the inherent responsiveness of the developing hematopoietic system to external forces and influences. We also established a serum-free system that facilitates directed differentiation, determining 5 ng/ml bone morphogenetic protein-4 (BMP4) with 50 ng/ml thrombopoietin (TPO) could generate 292 ± 42 colony forming cells (CFC)/5 x 10^4 cells with early VEGF treatment (25 ng/ml, day 0-5). We also controlled aggregate size influencing relative endogenous and exogenous growth factor signaling and modulating mesodermal differentiation; CFC output was optimal when initialized with 100 cell aggregates. For the first time, we demonstrated efficacy of local growth factor delivery by producing HPCs with gelatin microparticles (MP). Overall, these design components generate HPCs in a controlled and reproducible manner using a serum-free bioprocess that couples size controlled aggregates containing gelatin MPs for localized growth factor release of BMP4 and TPO with hypoxia to induce endogenous VEGF production. These strategies provide a tunable platform for developing cell therapies and high density growth, within a bioreactor system, can be facilitated by hydrogel encapsulation of the aggregates.

Statement of problem: We have shown that the C677T 5,10 methylenetetrahydrofolate reductase (MTHFR) variant is associated with elevated maternal serum α-fetoprotein (MSAFP), the most common screening test for neural tube defects (NTD). Therefore, past contradictory studies of NTDs and C677T MTHFR may have been biased because of changes in case populations after prenatal diagnosis and termination of pregnancy. Further, an unexplained elevation of MSAFP is known to increase the risk for later pregnancy complications. Is the C677T MTHFR variant a predisposing genetic variant for both NTDs and later complications of pregnancy? Methods: A retrospective study of women with pregnancies resulting in NTD outcome and women with unexplained elevations of MSAFP was undertaken. Women and their partners were genotyped for the C677T MTHFR allele. Couples with a pregnancy resulting in a NTD outcome were compared to couples whose pregnancy outcome did not involve. Couples with unexplained elevations of MSAFP who did and did not have later complications of pregnancy were also compared. Allele frequencies for all groups were then compared against the previously established Manitoba population allele frequency (based on 977 consecutive newborn metabolic screening bloodspots). A review of all studies of NTDs and association with the C677T MTHFR variant was undertaken to determine if the association between the variant and MSAFP is a source of bias. NTD incidence was examined before and after folic acid food fortification introduced in Canada in 1999. Results: There is an increase in the allele frequency of the C677T MTHFR variant in parents with an unexplained elevated MSAFP followed by later complications of pregnancy. The C677T MTHFR variant is also a contributing genetic factor to NTDs worldwide. The incidence of NTDs in Manitoba has decreased by 37% since food fortification with folic acid was introduced. Conclusions: The C677T MTHFR variant is a contributing genetic factor to both later complications of pregnancy after an unexplained elevation of MSAFP and to NTDs. This variant is folate sensitive and folic acid fortification has reduced the incidence of NTDs. / February 2005

This thesis presents a study on the enhancement of CHO cell growth by Yeast extract, Yeastolate, and Primatone fractions obtained by dead-end ultrafiltration. The total solid, peptide contents, antioxidant capacity and hydrophobicity of the fractions were evaluated. The objective of this project was to evaluate the potential of sequential ultrafiltration as an effective, simple and economical method for the identification of CHO cell growth enhancement components in yeast extract and yeastolate (primatone). The fractionation by sequential ultrafiltration (50 kDa membrane, 3 kDa membrane and 1 kDa membrane) of yeast extract (YE), yeastolate (YET), and primatone (PRI) showed different fouling and fractionation behaviour. Significant fouling was observed with the 50 kDa and 3 kDa membrane while negligible fouling was observed with the 1 kDa membrane. Similar and more significant fouling was observed with the 50 kDa membrane and for YE and PRI in comparison to YET. In contrast, more fouling was observed during the ultrafiltration with the 3kDa MWCO and for YE and YET in comparison to PRI. Finally a relatively constant permeate flux was obtained with the 1 kDa membrane, with PRI the highest and YET the lowest permeate flux. Different total peptide contents were present in the three feeds, 410, 327 and 300 mmol Phe-Gly equivalent/ g total solids for YE, PRI and YET respectively. In spite of different feed equivalent Phe-Gly, all three feeds contained a similar amount of equivalent Phe-Gly with molecular weight larger than 50 kDa, 15-19% of the initial feed stream. This was similar amount to the total solids content. The total peptide content of the retentate obtained for the 3kDa filtration indicated that YE and YET contained ~ 20% of equivalent Phe-Gly larger than 3 kDa but smaller than 50kDa. In contrast, PRI contained only 6% of equivalent Phe-Gly with such molecular weight. The retentate of the 1kDa filtration contained 55% of the feed equivalent Phe-Gly compared to 47% for YE and 38% for YET (p< 0.05). All three feeds have similar total peptide content smaller than 1 kDa. For any given feed, the equivalent Phe-Gly was larger than 1 kDa but smaller than 3 kDa predominated. The total peptide content profile according to size coincides with the total solids distribution for all three feed types. This is the first study that reports on the total peptide content for YE, YET, and PRI subjected to ultrafiltration fractionation. All three feeds and their fractions when freeze-dried had similar antioxidant capacity estimated by the FCR (Folin-Ciocalteu reagent) assay, ~ 40-50 mg Trolox/g sample. The bioactivity of feed and fractions was measured as cell density for CHO (beta-IFN producers) in basal medium supplemented with a combination of the crude non-fractionated feed material and a specific fraction and grown in T25 flasks. PRI showed a similar growth enhancement effect for all fractions when compared to a culture supplemented with the crude non-fractionated. YE showed no growth enhancement for any of the fractions when compared to a culture supplemented with the crude non-fractionated YE. This observation need to be confirmed as a culture supplemented with the crude non-fractionated YE showed a very high growth stimulating effect which was much higher than PRI and YET at the same concentration. Finally, YET 3kDa retentate fraction displayed a 50 % growth enhancement effect. In conclusion, the fractions obtained from the two non-animal protein hydrolysates considered in this study, YE and YET showed limited CHO cell growth enhancement effect when compared to the non-fractionated material. Only the YET 3kDa retentate fraction displayed a good CHO cell growth enhancement effect. YET 3kDa represent an attractive serum substitute for its use in culturing CHO cells. PRI, an animal derived protein hydrolysate showed the best growth enhancement effect for all fractions produced in this study. These results suggest that YET has high potential as a media additive for the development of serum-free media which can promote cell growth and, in the future this work can contribute in production of therapeutic proteins markets.